Peter T. Nash
Impact in
- Rheumatology top 0.01%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
- Immunology top 0.5%
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
Papers in
- Rheumatology 249
- Spondyloarthritis Studies and Treatments 141
- Rheumatoid Arthritis Research and Therapies 100
- Systemic Lupus Erythematosus Research 6
-
- Systemic Sclerosis and Related Diseases 20
- Co-authors
- Philip J. Mease (70 shared papers)Dafna D. Gladman (31 shared papers)Daniel O. Clegg (2 shared papers)Christian Antoni (1 shared paper)Désirée M F M van der Heijde (17 shared papers)Luminita Pricop (33 shared papers)Iain B. McInnes (39 shared papers)Frank Behrens (21 shared papers)
- Journals
- Annals of the Rheumatic Diseases (62 papers)Lara D. Veeken (24 papers)Rheumatology and Therapy (22 papers)The Journal of Rheumatology (16 papers)RMD Open (14 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Peter T. Nash
324 papers receiving 20.8k citations
Peter T. Nash's Hit Papers
Peers
Comparison fields: 5 of 110
- Rheumatology 13.1k
- Immunology 1.5k
- Pathology and Forensic Medicine 1.0k
- Family Practice 74
- Orthopedics and Sports Medicine 235
Countries citing papers authored by Peter T. Nash
This map shows the geographic impact of Peter T. Nash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter T. Nash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter T. Nash more than expected).
Fields of papers citing papers by Peter T. Nash
This network shows the impact of papers produced by Peter T. Nash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter T. Nash. The network helps show where Peter T. Nash may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter T. Nash, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 330 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Hit paper breakdown → | 2017 | 4893 |
| 2 | Psoriatic arthritis: epidemiology, clinical features, course, and outcome Hit paper breakdown → | 2005 | 1267 |
| 3 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Hit paper breakdown → | 2015 | 1165 |
| 4 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis Hit paper breakdown → | 2016 | 743 |
| 5 | Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis Hit paper breakdown → | 2015 | 637 |
| 6 | 2004 | 539 | |
| 7 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Hit paper breakdown → | 2013 | 487 |
| 8 | 2008 | 459 | |
| 9 | 2009 | 358 | |
| 10 | Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials Hit paper breakdown → | 2017 | 341 |
| 11 | Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Hit paper breakdown → | 2017 | 340 |
| 12 | 2004 | 339 | |
| 13 | 2010 | 309 | |
| 14 | 2013 | 302 | |
| 15 | 2015 | 282 | |
| 16 | 2012 | 260 | |
| 17 | 2008 | 254 | |
| 18 | 2019 | 238 | |
| 19 | Consensus on a core set of domains for psoriatic arthritis. | 2007 | 235 |
| 20 | Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement Hit paper breakdown → | 2020 | 226 |
About Peter T. Nash
Peter T. Nash is a scholar working on Rheumatology, Pathology and Forensic Medicine, Immunology, Pulmonary and Respiratory Medicine and Orthopedics and Sports Medicine, having authored 330 papers that have together received 21.7k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (141 papers), Rheumatoid Arthritis Research and Therapies (100 papers), Systemic Sclerosis and Related Diseases (20 papers), Pulmonary Hypertension Research and Treatments (11 papers), Psoriasis: Treatment and Pathogenesis (9 papers), Systemic Lupus Erythematosus Research (6 papers), Bone health and osteoporosis research (5 papers) and Inflammatory Myopathies and Dermatomyositis (3 papers). The work is most often cited by research in Rheumatology (13.1k citations), Immunology (1.5k citations), Pathology and Forensic Medicine (1.0k citations), Family Practice (74 citations) and Orthopedics and Sports Medicine (235 citations). Peter T. Nash has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Philip J. Mease, Dafna D. Gladman, Daniel O. Clegg, Christian Antoni, Désirée M F M van der Heijde, Luminita Pricop, Iain B. McInnes, Frank Behrens, Paul E. Emery and Yoshiya Tanaka. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Rheumatology and Therapy, The Journal of Rheumatology and RMD Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.